GlucoTrack Inc Dossier - Source-backed chat

GlucoTrack Inc

GCTKNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.79

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.41Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.4M

Enterprise Value $1.1M

Shares Outstanding 798.4K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Glucotrack, Inc. is a development-stage medical technology company focused on a highly differentiated, fully implantable continuous blood glucose monitoring (CBGM) system that measures glucose directly from the bloodstream. While clinical data from first-in-human trials in Brazil and Australia demonstrate excellent accuracy (MARD of 7.7%) and safety, the company faces severe near-term financial and regulatory risks. With cash reserves of $3.9 million as of March 31, 2026, the runway only extends into early Q3 2026. Furthermore, the company has received Nasdaq deficiency notices regarding its minimum bid price and stockholders' equity. Although shareholders have authorized capital-raising mechanisms and a reverse stock split of up to 1-for-30, the impending dilution and delisting risks warrant a cautious 'Hold' recommendation until the U.S. clinical trials are initiated and additional long-term funding is secured.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.4920%

The company fails to raise sufficient capital or execute the reverse split in a timely manner, leading to delisting from the Nasdaq Capital Market. FDA approval of the IDE is delayed due to safety or protocol questions, halting the U.S. clinical program and severely impairing the company's viability as a going concern.

Base CaseCentral scenario

$1.2255%

Glucotrack executes a reverse stock split to regain compliance with Nasdaq's minimum bid price rule and utilizes its equity line with Sixth Borough Capital Fund to extend its cash runway. The FDA approves the IDE, and U.S. clinical trials begin in late 2026, though progress is slowed by ongoing capital constraints and high dilution.

Bull CaseUpside scenario

$1.8425%

The FDA approves the company's IDE application, allowing the launch of U.S. human clinical trials in H2 2026. The trials replicate the strong safety and accuracy profiles seen in previous studies (MARD < 8.0% with zero serious adverse events). Glucotrack successfully secures non-dilutive strategic partnerships or executes its equity line with minimal market disruption, resolving its going concern doubts and regaining Nasdaq compliance.

Scenarios reflect our research view at the research date.

Key Investment Merits

Differentiated intravascular approach measuring glucose directly from blood, eliminating the 10-minute lag time associated with interstitial fluid CGMs.
Long-term sensor design targeting up to three years of longevity with no on-body wearable components.
Strong clinical feasibility data with a 7.7% MARD and 99% data capture rate in first-in-human trials.

Key Investment Risks

Extremely limited cash runway extending only into early Q3 2026, creating an urgent need for dilutive capital raises.
Nasdaq delisting risk due to non-compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) requirements.
High execution and regulatory risk associated with obtaining FDA approval for a Class III implantable medical device.

Thesis Invalidation Triggers

FDA rejection or prolonged hold of the Investigational Device Exemption (IDE) application.
Delisting from the Nasdaq Capital Market.
Inability to secure additional financing before the depletion of existing cash in early Q3 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.